Log in

TSE:FRXFennec Pharmaceuticals Stock Price, Forecast & News

C$11.44
+0.25 (+2.23 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
C$11.43
Now: C$11.44
C$11.44
50-Day Range
C$9.95
MA: C$11.18
C$12.70
52-Week Range
C$5.00
Now: C$11.44
C$13.24
Volume205 shs
Average Volume1,422 shs
Market CapitalizationC$290.07 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-919-6364530

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.36 per share
Book ValueC$0.43 per share

Profitability

Miscellaneous

Employees3
Market CapC$290.07 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive FRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.

Fennec Pharmaceuticals (TSE:FRX) Frequently Asked Questions

How has Fennec Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Fennec Pharmaceuticals' stock was trading at C$9.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FRX stock has increased by 26.8% and is now trading at C$11.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Fennec Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fennec Pharmaceuticals.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Fennec Pharmaceuticals.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (TSE:FRX) issued its quarterly earnings data on Thursday, May, 14th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.26). View Fennec Pharmaceuticals' earnings history.

Has Fennec Pharmaceuticals been receiving favorable news coverage?

Headlines about FRX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fennec Pharmaceuticals earned a news impact score of 1.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Fennec Pharmaceuticals.

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, CEO & Director (Age 43)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 44)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 65)

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "FRX."

How do I buy shares of Fennec Pharmaceuticals?

Shares of FRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FRX stock can currently be purchased for approximately C$11.44.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of C$290.07 million. Fennec Pharmaceuticals employs 3 workers across the globe.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is fennecpharma.com.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company can be reached via phone at +1-919-6364530.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.